n prodrug -activated or``suicide'' gene therapy, a gene coding for an enzyme that converts a nontoxic prodrug into a lethal compound is inserted into tumor cells. 1 The most studied system uses the herpes simplex virus -1 thymidine kinase ( HSV1 -TK ) gene and the prodrug ganciclovir (GCV ) . HSV1 -TK functions by selectively phosphorylating GCV to a monophosphate form. Cellular kinases further phosphorylate the monophosphate to di-and triphosphate metabolites; the triphosphorylated form is the active compound. 2 The incorporation of triphosphorylated GCV into DNA results in chain termination and consequently cell death. 3 Normal cells cannot phosphorylate GCV and are therefore insensitive to it; however, insertion of the suicide gene into tumor cells results in tumor destruction following GCV treatment. 4 In animal models, HSV1 -TK and GCV have significant antitumor activity against a range of tumors including glioma, 5, 6 sarcoma, 7 melanoma, 8, 9 prostate, 10 and colon carcinoma. 11 ± 13 Interestingly, some studies have demonstrated that for almost total tumor regression, only 10 ±20% of the tumor mass needs to express the HSV1 -TK gene. 7, 11 The death of neighboring, unmodified cells is known as thè`b ystander effect''. This mechanism makes HSV1-TK gene therapy clinically attractive as relatively low transduction efficiency would be required in vivo to achieve significant tumor regression. The bystander effect is believed to be mediated partly by the transfer of phosphorylated compounds, via gap junctions, into neighboring cells, 14 ± 17 and partly by local immune responses. 1, 18, 19 Several studies have demonstrated the immunological component of the bystander effect. Nude mice are impaired in their ability to effect suicide gene -mediated tumor regression, 8, 12 treatment generates systemic antitumor immunity, 8, 20, 21 and tumor regression is associated with a significant leukocytic infiltrate 11, 19, 22, 23 and cytokine release. 19, 23, 24 Other therapeutic approaches being considered involve the transfer of cytokine genes into tumor cells. A number of cytokines, including GM -CSF, 25 ± 31 IL -2, 27 ± 29,32,33 IL -12, 34 ± 36 and IFN -, 28 are effective inhibitors of tumor growth. The antitumor effects produced during cytokine gene therapy and the strong evidence for immunological involvement in suicide gene therapy have resulted in several studies combing the two approaches. Recent data indicate that tumor regression is enhanced when suicide and cytokine gene therapy are combined. 37 ± 42 Moreover, cytokine gene therapy appears, in some protocols, to generate a systemic antitumor immune response. 37,41 ± 43 The present study examined the effectiveness of HSV1 -TK suicide and GM -CSF gene therapy in inducing tumor regression and subsequent tumor immunity in a syngeneic murine model of colorectal carcinoma. GM -CSF was selected as our preliminary data, and those of others 38, 39 have shown that this combination is effective. To generate an antitumor immune response, tumor antigens must be released from tumor cells, processed by antigen -presenting cells ( APCs ) , and presented to antigen-specific T cells. GM -CSF has several functions, which promote the generation of an immune response, including the activation and expansion of neutrophils, monocytes, and dendritic cells, 44, 45 and the up-regulation of cell surface co-stimulatory molecules required for T-cell activation. 46, 47 As HSV1 -TK ± and GCV-mediated tumor cell lysis releases tumor antigens, we propose that the presence of GM -CSF in the tumor microenvironment enhances antigen uptake and presentation by APCs. This results in the generation of antitumor immunity, which enhances tumor regression and protects against recurrence.
MATERIALS AND METHODS

Cell lines
MC26, a BALB / c (H -2 d ) murine carcinogen -induced colon carcinoma cell line, 48 was routinely maintained in RPMI medium containing 10% fetal calf serum ( FCS, Harlan Sera -Lab, Crawley Down, UK ). The cell line was the kind gift of Dr. C. Townsend, Jr. ( Department of Surgery, University of Texas, Galveston, TX ). The murine fibrosarcoma cell line, KBALB, was used as a control syngeneic (H -2 d ) tumor. It was obtained from the European Collection of Cell Cultures (Porton Down, UK ) and routinely maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS.
Vectors and transduction
The HSV1 -TK ± expressing pLJ -TK vector was constructed by cloning the 1130-bp coding sequence of HSV1 -TK into the BamHI site of pLJ. 49 It was transduced into MC26 cells using a standard in vitro transduction using the pLJ -TK packaging cell line 12 and cells were selected and maintained in RPMI+ 10% FCS containing 1 mg /mL G418 ( MC26 -TK ). This vector was the kind gift of Prof. D. Klatzmann ( L'Ho Ãpital de la Pitie Â Salpe Átrie Âre, Paris, France ).
The GM -CSF ±expressing pxLNC -GMCSF vector was constructed by cloning the 430 -bp coding sequence of murine GM -CSF into the BamHI and KpnI sites of the pxLNC plasmid. 50 It was then transduced into MC26 cells by retroviral transduction using the FLYA13 -GM -CSF packaging cell line, which was the kind gift of Drs. P.F. Searle and R. Doshi ( Institute for Cancer Studies, University of Birmingham, UK ). Transduced cells were grown in the presence of G418 until clones appeared. Individual clones were then selected and maintained in G418. GM -CSF secretion was measured by culturing 10 6 cells /mL for 72 hours. The amounts of cytokine in the culture supernatants were determined by enzyme-linked immunosorbent assay ( Endogen, Boston, MA ) . The clone with the highest titer of GM -CSF was used in subsequent experiments ( MC26 -GM -CSF ) .
Sensitivity to GCV in vitro
Cells transduced with HSV1-TK were tested for their sensitivity to GCV ( Cymevene, Roche Products, Welwyn Garden City, UK ) in a proliferation assay. MC26 -TK cells and unmodified MC26 cells were plated at different ratios ( 100:0, 95:5, 90:10, 80:20, 70:30, 50:50, 0:100 ) in flatbottomed 96 -well microtiter plates (10 4 cells/ well ). After 20 hours, GCV was added to give final concentrations of 4.58, 1.14, and 0.57 g /mL; control wells contained medium and cells alone, medium and GCV alone, or medium only; each combination was performed in triplicate. After 48 -hour incubation, the wells were pulsed with 0.4 Ci / well [ 3 H ]thymidine ( Amersham Life Sciences, Little Chalfont, Bucks ) diluted in phosphate -buffered saline for 6 hours and then harvested. Tritiated thymidine incorporation, as an indication of cellular proliferation, was measured using a microplate scintillation counter ( Top Count, Packard Pangbourne, Berks, U.K. ). The results were expressed as mean counts per minute ( cpm ) SEM. On day 0, tumors were established by subcutaneous injection of tumor cells into the left flank of each mouse. Different experimental groups were injected with different combinations of modified and unmodified MC26 tumor cells. Twelve mice received tumor inocula containing only unmodified MC26, 15 mice received 50% MC26 and 50% MC26 -TK cells, 12 received 50% MC26 and 50% MC26-GM -CSF cells, 12 received 50% MC26 -TK and 50% MC26 -GM -CSF cells. The tumors were left to develop for 7 days before the mice were treated twice daily for 5 days with intraperitoneal GCV (75 mg / kg/body weight) or saline ( groups of five to seven mice) . On day 13, all mice were sacrificed and the entire subcutaneous tumor excised.
Experimental tumor induction
Using a computerized Digimatic digital vernier calliper ( Mitutoyo Andover, Hants, U.K. ), the longest diameter ( l), the width ( w ), and the height ( h) were measured to the nearest 0.01 mm. Tumor volume was calculated using the following formula:
Statistically significant differences in tumor volumes between the groups were assessed using the nonparametric Mann -Whitney U test. A P value of <.05 was considered significant.
At the time of sacrifice, the spleen was also removed and used in a standard chromium release assay to assess antitumor lytic activity.
The above experiment was repeated using reduced proportions of modified tumor cells in the inoculum: 75% MC26 /25% MC26 -TK ( n= 9) ; 50% MC26 /25% MC26-TK /25% MC26 -GM -CSF ( n =5 ); 90% MC26/ 10% MC26 -TK ( n= 5 ); 80% MC26 /10% MC26 -TK / 10% MC26 -GM -CSF ( n= 5) ; 95% MC26/5% MC26-TK ( n= 5) ; 90% MC26/ 5% MC26-TK / 5% MC26-GM -CSF ( n= 5) . All the mice in these groups were treated with GCV.
A similar experiment, to examine the development of antitumor lytic activity post -treatment, was carried out using seven mice inoculated with 50% MC26 and 50% MC26-TK cells. These mice were treated with GCV, as previously described, but sacrificed 14 days after the cessation of GCV treatment on day 27. Their tumor volumes were measured and splenocytes isolated and used to assess antitumor lytic activity.
Chromium release assay
This assay was performed according to standard protocols. 52 Splenocytes were isolated by mechanical disaggregation in phosphate -buffered saline containing 1% FCS and red blood cells lysed by osmotic shock. The splenocytes were washed and stimulated in vitro for 6 days by culturing 2.4Â10 7 splenocytes in 25 mL RPMI containing 10%FCS and 20 U / mL recombinant mIL -2 ( Serotec, Oxford, UK ) with 2Â10 6 MC26 cells that had received 150 Gy of -irradiation. On day 7, the stimulated effector cells were co -incubated in triplicate with 51 Cr-labeled MC26 target cells for 4 hours at 378C at different effector-to -target ratios. The data were expressed as the percentage specific chromium release ( %SCR ) at a 20:1 effector-to -target ratio:
% specific chromium release % SCR experimental release À spontaneous release maximum release À spontaneousrelease Â 100
Statistical differences in the %SCR between groups were assessed using Student's t test.
Tumor recurrence following GCV treatment of HSV1 -TK ± and GM -CSF ± expressing subcutaneous MC26 tumors Two groups of eight mice were inoculated with MC26 tumor cells: one group received an inoculum composed of 50% unmodified and 50% HSV1 -TK ± expressing cells; the other group received 50% HSV1 -TK ± and 50% GM -CSF ± expressing cells. After 7 days, the animals were treated with GCV as previously described. Following the completion of treatment, the animals were monitored for 96 days and regularly assessed by palpation for the presence of tumors. Animals that developed a tumor were sacrificed and their splenocytes examined for the presence of antitumor lytic activity. Statistically significant differences in tumor volumes between the groups were assessed using the nonparametric Mann -Whitney U test. A value of P < .05 was considered significant.
Tumor rechallenge following GCV treatment of HSV1 -TK ± and GM -CSF ± expressing subcutaneous MC26 tumors Forty mice were inoculated on their left flanks with tumors composed of 50% HSV1 -TK ± and 50% GM -CSF ± expressing MC26 cells. Following development of the tumor and GCV treatment, as previously described, the 35 animals that remained tumor-free were divided into three groups. In the first group, 13 mice were rechallenged on day 27 with either 10 6 unmodified MC26 cells (n =7 ) or KBALB cells ( n= 6 ) ( control tumor ) on their right flanks. The tumors were allowed to develop for 11 days before the animals were sacrificed and their tumors excised and measured. The spleens were also removed for assessment of antitumor lytic activity in a chromium release assay (as previously described ). The animals in group 2 ( n= 9 ) were rechallenged on day 41 with 10 6 unmodified MC26 cells as described above. The animals in group 3 were rechallenged on day 121 with either MC26 ( n= 7 ) or KBALB cells ( n=6).
Twenty-eight mice were used as control animals; on day 0, 12 were inoculated with 10 6 unmodified MC26, and 16 with 10 6 KBALB cells. The tumors were allowed to develop for 11 days before the mice were sacrificed and their tumor volumes measured. Statistical significance of differences in Cancer Gene Therapy, Vol 7, No 12, 2000 JONES, POPE, KINSELLA, ET AL: GM-CSF BOOSTS TUMOR IMMUNITY IN SUICIDE GENE THERAPY tumor volumes and antitumor lytic activity between groups was assessed using the Mann -Whitney U test.
Adoptive transfer of antitumor immunity
Twenty-seven mice were inoculated on their left flanks with tumors composed of 50% HSV1-TK ± and 50% GM -CSF ± expressing cells. Following development of the tumor and GCV treatment, as previously described, the 24 mice, which remained tumor-free, were sacrificed on day 27 (2 weeks after the cessation of GCV treatment). Their spleens were removed and single cell suspensions of 5Â10 7 splenocytes / mL in HBSS prepared. By intraperitoneal injection, 5Â10 7 splenocytes from individual mice were then transferred back to 24 naõ Ève mice. The remaining splenocytes were pooled and used to reconstitute a further five mice in the same way. In addition, splenocytes from 14 mice were used to assess the presence of antitumor lytic activity.
The mice were then left for 2 weeks before being challenged on their right flank with either 10 6 unmodified MC26 ( n= 21 ) or KBALB cells (n =8 ). The mice were left for a further 11 days before being sacrificed and their tumor volumes measured. The spleens were also removed for assay of antitumor lytic activity.
In control experiments, 5Â10 7 splenocytes from 16 normal BALB /c mice were transferred into 16 naõ Ève mice. After 2 weeks, these mice were challenged with unmodified MC26 on their right flank as described above. The mice were left for 11 days before being sacrificed and their tumor volumes measured. Statistically significant differences in tumor volumes between the groups were assessed using the Mann -Whitney U test.
RESULTS
GCV sensitivity of MC26 in vitro after transduction with HSV1 -TK Figure 1 demonstrates that stable transduction of the HSV1 -TK vector into MC26 resulted in cell death after in vitro exposure to GCV at the three concentrations investigated; GCV administration had little effect on the growth of unmodified MC26 cells. This experiment also combined transduced and nontransduced MC26 cells in different ratios to address whether treatment of MC26 -TK cells with GCV resulted in the inhibition or death of neighboring unmodified cells. These data show that at the GCV concentrations investigated, as few as 30% of the MC26 cells expressing the HSV1 -TK gene was sufficient to inhibit cellular proliferation completely. When the level of HSV1 -TK ±expressing cells was reduced to 5%, there was still a significant inhibition of cellular proliferation compared with the control ( 90.1%, 76.9%, and 61.9% inhibition at 4.58, 1.25, and 0.625 g/ mL GCV, respectively ) . These data illustrate that a strong bystander effect is operative in this in vitro system. GCV treatment of HSV1 -TK ± and GM -CSF ± expressing MC26 tumors GM -CSF ± transduced MC26 cells spontaneously produced 422 ng /mL GM -CSF /10 6 cells over 72 hours, compared with nontransduced MC26 cells that produced 0.4 ng/ mL. Figure 2 shows the effect of GCV and saline treatment on tumors in mice inoculated with different combinations of unmodified, HSV1 -TK, or GM -CSF gene -expressing MC26 cells. In the saline -treated mice, there were no significant differences in tumor volumes between the groups; thus, there were no differences in the growth of tumors composed of modified and unmodified MC26 cells. There was, however, a significant reduction in tumor volume in GCV-treated mice inoculated with 50% HSV1 -TK ±expressing cells compared with unmodified MC26 only ( P= .0015 ) . Similarly, tumors in mice inoculated with 50% MC26 -TK and 50% MC26-GM -CSF were significantly smaller than those inoculated with MC26 only ( P= .0022 ). There was no significant difference in tumor volumes between the MC26 -TK ± containing and GCVtreated groups.
In order to assess the potency of HSV1 -TK ±contain-ing cells in inducing tumor regression, tumors were induced with decreasing proportions of MC26 -TK in combination with unmodified MC26 and MC26 -GM -CSF cells. As shown in Table 1 , tumors with as few as 10% MC26-TK cells were not significantly larger than those with 50% MC26-TK, and only in the group inoculated with 95% MC26 /5% MC26 -TK were tumors signifi- Differences from the group given 50% MC26 / 50% MC26 -TK were significant: *P < .05; **P < .005; all other differences were not significant. 
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cantly larger (P=.0007) . All tumors were significantly smaller than those from mice inoculated with unmodified MC26 cells. Groups inoculated with cell mixtures containing 25%, 10%, and 5% HSV1 -TK ± and GM -CSF ± expressing cells also produced significantly smaller tumors than control ( 100% MC26; P= 0.006 ). When compared with 50% MC26 -TK /50% MC26 -GM -CSF inoculated mice, 90% MC26 /10% MC26-TK, 75% MC26 /25% MC26 -TK, and 50% MC26/ 25% MC26 -TK /25% MC26 -GM -CSF tumors were not significantly different. Tumors in mice receiving 95% MC26/ 5% MC26-TK, 90% MC26 / 5% MC26 -TK /5% MC26 -GM -CSF, or 80% MC26/ 10% MC26-TK /10% MC26 -GM -CSF cells, however, were significantly larger (P=.006).
Tumor recurrence following GCV treatment of HSV1 -TK ± and GM -CSF ± expressing subcutaneous MC26 tumors
The data in Figure 2 illustrate almost complete tumor regression after GCV treatment of MC26 tumors expressing the HSV1 -TK gene in combination with either unmodified or GM -CSF ±expressing cells. It was unclear, however, whether any remaining tumor was viable and would regrow. The results presented in Figure  3 demonstrate that by day 13, the majority of mice in each group still had palpable tumors. By day 20, however, approximately 75% of the mice in the combined HSV1 -TK / GM -CSF group had no detectable tumor. In contrast, in the unmodified /HSV1 -TK group, less than 40% was tumorfree. By day 50, tumors had recurred in all mice in the unmodified /HSV1 -TK group; in the combined group, 75% of the mice remained tumor-free until the end of the experiment. These data demonstrate that in the period after GCV treatment, combined HSV1-TK and GM -CSF treatment is more effective than HSV1 -TK alone in preventing tumor recurrence.
Tumor rechallenge following GCV treatment of HSV1 -TK ± and GM -CSF ± expressing subcutaneous MC26 tumors
Tumor-free animals after HSV1-TK /GM -CSF inoculation and GCV treatment were rechallenged with unmodified MC26 cells on the opposite flank. At all three time points, the majority of rechallenged animals failed to develop tumors and mean tumor volumes were significantly smaller than those in naõ Ève mice ( Fig 4 ) . In contrast, when mice were injected with control KBALB cells, tumor volumes were not significantly smaller than those in naõ Ève mice. Figure 5 shows that transfer of splenocytes from HSV1-TK /GM -CSF ±treated mice into naõ Ève mice produced significantly smaller tumors compared with control mice ( transferred with splenocytes from naõ Ève mice ) (P=.03). Similarly, when the splenocytes from treated mice were pooled prior to transfer, the tumors generated were significantly smaller than controls (P=.03).
Adoptive transfer of antitumor immunity
Detection of splenocyte antitumor lytic activity
In order to test for the presence of specific antitumor cytotoxicity, splenocytes from different groups of mice were assayed for their ability to kill unmodified MC26 cells. The splenocyte lytic activities generated by various protocols are presented in Table 2 . Investigation of antitumor lytic activity from the saline-( data not shown) and GCV-treated mice sacrificed at day 13 ( tumor volume data in Fig 2) showed negligible activity in all groups. However, in the MC26 / MC26-TK ± and MC26 -TK /MC26 -GM -CSF ± inoculated animals sacrificed at day 27, there was a significant increase in the lytic activity compared with day 13 (MC26/ MC26 -TK, P=.028; MC26-TK /MC26-GM -CSF, P=.002 ). On day 96, the surviving animals originally inoculated with MC26-TK ± and MC26 ± GM -CSF ± expressing cells had elevated lytic activity, significantly higher than at days 13 ( P= .0034 ) and 27 (P=.0094 ). Elevated antitumor lytic activity was detected in the animals that were originally inoculated with MC26 -TK /MC26-GM -CSF and rechallenged after 14 and 28 days.
DISCUSSION
These data clearly demonstrate that GCV treatment effectively induced regression of HSV1 -TK ±expressing colon tumors, in agreement with previous studies.
11 ,12 In vitro proliferation assays and significant regression in vivo of tumors in which only 5% of cells expresses the suicide gene also confirm the presence of a strong bystander effect. However, in all cases, tumors recurred, as previously reported. 43 The present study examined whether the effectiveness of HSV1 -TK suicide gene therapy could be improved by combining it with GM -CSF gene therapy.
Examination of tumor regression over a 13 -day period demonstrated significant regression of GCV-treated HSV1 -TK ±expressing tumors; the inclusion of GM -CSF ±expres-sing cells had no further effect. Previous studies, however, have reported that genetic modification of tumor cells to express GM -CSF reduced their tumorigenicity by making them more immunogenic. 25 ± 31 The control experiments illustrate that, in vivo and in vitro (HSV1-TK ± modified only ), the growth of tumors expressing HSV1 -TK and /or GM -CSF was not significantly different from unmodified MC26 tumors. Experiments that reduced the proportion of suicide gene expressing cells to 25%, 10%, and 5% still showed significant tumor regression. However, as the proportion decreased, the residual tumor remaining after treatment increased compared with a tumor inoculum containing 50% MC26-HSV1 -TK ± expressing cells. Combination with GM -CSF ± expressing cells at these low levels did not result in any reduction in tumor volume above that obtained with the suicide gene only. Indeed, the group given 10% MC26 -TK / 10% MC26 -GM -CSF actually developed significantly larger tumors than the 90% MC26/10% MC26 -TK group (Table 1) . This suggests that the immunological mechanisms enhanced by GM -CSF may not begin to operate until after the short period of GCV treatment. These results may differ from previous studies because tumor volumes were assessed immediately after GCV treatment.
Although there were no significant differences in the size of tumors immediately after cessation of GCV treatment, tumors only regrew in mice that were given HSV1 -TK ±expressing cells without GM -CSF. Most mice in the combination group eradicated residual tumor after treatment, remaining tumorfree for several months. These data emphasize the superior efficacy of combining suicide with GM -CSF gene therapy. Previous studies 25,26,28 ± 31,53 have documented the antitumor effects of GM -CSF gene therapy alone and in combination with suicide genes. 27 In the present study, tumors were not completely eradicated in either the HSV1 -TK or the combined treatment groups during GCV treatment. After GCV treatment, all tumors in the suicide -gene-only group subsequently regrew. It has been suggested that some tumor cells are resistant to GCV-mediated regression, 54 but it is not known whether the tumor cells that regrew were HSV1-TK positive. In contrast, in the combined group, tumor regression continued after GCV treatment, with the majority of animals becoming tumor-free.
During GCV treatment, tumor destruction occurs due to phosphorylation of GCV in transduced and neighboring cells. However, the addition of GM -CSF generated an antitumor immune response that led to continued tumor destruction after GCV treatment. The antitumor effects of GM -CSF have been attributed to enhanced antigen presentation. Initial destruction of the tumor during GCV treatment releases tumor antigens, whereas, concomitant production of GM -CSF enhances inflammation and activates APCs. Presentation of tumor antigens by activated APCs to CD4 + T cells, attracted to the tumor by the enhanced inflammatory reaction, begins a cell -mediated antitumor immune response. Previous studies, 12 using the HSV1 -TK gene only, have shown an infiltration of CD8 + T cells into the periphery of the regressing tumor. MC26 cells have been reported to be sensitive to lysis by class I MHCrestricted CD8 + T cells both in vitro and in vivo. 55 However, our data do not support the production of an effective cellmediated immune response in the HSV1 -TK only group. Alternatively, in the combined group, activated APCs and CD4 + T cells ( via IL -2 ) may stimulate CD8 + T cells, allowing the generation of a population of antitumor effector cells. The significant increase in antitumor lytic activity in this group indicates that CD8 + T cells facilitate tumor regression post -treatment. The small tumor volumes after GCV treatment in the regressed groups prevented examination of intratumoral CD8 + T cells. Rechallenge and adoptive transfer experiments also support the generation of an antitumor immune response as a result of combined HSV1-TK and GM -CSF gene therapy. Although previous studies have demonstrated that combined treatment can effectively lead to tumor regression, 27, 41 ,43 the present study shows that treatment can protect the animal against rechallenge with unmodified tumor. The long -and short -term rechallenge experiments showed that most mice were immune to MC26. Moreover, rechallenge with the control tumor (KBALB ) produced large tumors demonstrating that the immunity generated was tumor-specific. Cytotoxicity experiments also showed high levels of antitumor lytic activity in rechallenged mice. The levels detected in the rechallenged animals were generally higher than those in mice that had not been rechallenged. This may be a result of the expansion in vivo of tumor-specific effector cells after tumor inoculation. Consequently, after sacrifice, levels of splenic effector cells were higher than those in resting animals, producing higher lytic activity in the assay. In agreement with previous studies, 37, 43, 56 the demonstration of specific CTL activity in vitro required several days of culture with irradiated tumor cells in the presence of IL-2, indicating that reactivation of memory CD8 + T cells was occurring. 56 The adoptive transfer experiments showed that transfer of splenocytes from mice treated by combined HSV1 -TK and GM -CSF gene therapy into naõ Ève mice conferred some protection against tumor challenge. These data confirm that the previous findings are due to immunological mechanisms. Moreover, they act as a basis for future investigation into the type of cells, and the mechanisms, that are active during combined gene therapy. Future work will investigate the requirements for CD4 + and CD8 + T cells as well as NK cells in both the elimination of established tumors and the adoptive transfer of immunity. Clinically, these findings are encouraging as the generation of antitumor immunity during regression of a primary tumor may act to remove nonresectable metastatic deposits and prevent tumor recurrence. This approach is also attractive as the immune system can be manipulated without the need to characterize tumor antigen expression.
These present data highlight that combining suicide and cytokine gene therapy may be more efficacious as a result of enhanced immunological activity. Future studies should address whether this approach is equally effective against established tumors that may have mechanisms to subvert antitumor immune responses. This study has demonstrated that HSV1 -TK is effective even at very low transduction levels, although it remains unclear whether lower levels of GM -CSF ± producing cells will induce a similarly effective immune response. Previous studies 39 have reported that the effects of GM -CSF are dose -dependent and high levels may be required to overcome the immunosuppressive cytokines, which down -regulate tumor antigen presentation. 57 
